MCID: SFT003
MIFTS: 56

Soft Tissue Sarcoma

Categories: Rare diseases

Aliases & Classifications for Soft Tissue Sarcoma

MalaCards integrated aliases for Soft Tissue Sarcoma:

Name: Soft Tissue Sarcoma 52 58 29 42 17
Non-Rhabdomyosarcoma Soft Tissue Sarcoma 52
Malignant Mesenchymal Tumor 58
Malignant Soft Tissue Tumor 58
Connective Tissue Sarcoma 52
Sarcoma, Soft Tissue 39
Soft Part Sarcoma 58
Sarcoma 71

Characteristics:

Orphanet epidemiological data:

58
soft tissue sarcoma
Prevalence: 1-5/10000 (Europe);

Classifications:



External Ids:

UMLS via Orphanet 72 C0334492 C1261473
Orphanet 58 ORPHA3394
UMLS 71 C1261473

Summaries for Soft Tissue Sarcoma

NIH Rare Diseases : 52 Soft tissue sarcoma is a form of cancer that occurs due to abnormal and uncontrolled cell growth of the "soft tissues" of the body. These tissues connect, support and surround other body parts and may include muscle, fat, blood vessels, lymph vessels , nerves, tendons and the lining of joints. Many people with early soft tissue sarcoma have no signs or symptoms of the condition. When present, symptoms depend on the location and size of the tumor but may include a palpable lump under the skin, pain, or difficulty breathing. Most cases occur sporadically in people with little to no family history of the condition. People who have previously received radiation therapy and those with certain inherited disorders (such as Gorlin syndrome , Gardner syndrome , Li-Fraumeni syndrome , Tuberous sclerosis , neurofibromatosis type 1 , and Werner syndrome ) have an increased risk of developing a soft tissue sarcoma. The best treatment options depend on many factors but may include surgery, chemotherapy , and radiation therapy .

MalaCards based summary : Soft Tissue Sarcoma, also known as non-rhabdomyosarcoma soft tissue sarcoma, is related to myxoid liposarcoma and sarcoma, synovial. An important gene associated with Soft Tissue Sarcoma is MDM2 (MDM2 Proto-Oncogene), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Lopinavir and Lamivudine have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and t cells, and related phenotypes are cardiovascular system and hematopoietic system

MedlinePlus : 42 Your soft tissues connect, support, or surround other tissues. Examples include your muscles, tendons, fat, and blood vessels. Soft tissue sarcoma is a cancer of these soft tissues. There are many kinds, based on the type of tissue they started in. They may cause a lump or swelling in the soft tissue. Sometimes they spread and can press on nerves and organs, causing problems such as pain or trouble breathing. No one knows exactly what causes these cancers. They are not common, but you have a higher risk if you have been exposed to certain chemicals, have had radiation therapy, or have certain genetic diseases. Doctors diagnose soft tissue sarcomas with a biopsy. Treatments include surgery to remove the tumor, radiation therapy, chemotherapy, or a combination. NIH: National Cancer Institute

Wikipedia : 74 A soft-tissue sarcoma (STS) is a form of sarcoma that develops in connective tissue, though the term is... more...

Related Diseases for Soft Tissue Sarcoma

Diseases related to Soft Tissue Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 695)
# Related Disease Score Top Affiliating Genes
1 myxoid liposarcoma 33.0 TP53 MDM2 EWSR1
2 sarcoma, synovial 32.8 MDM2 FOXO1 EWSR1 BCL2
3 rhabdomyosarcoma 2 32.8 MDM2 FOXO1 EWSR1
4 malignant fibrous histiocytoma 32.7 TP53 MKI67 MDM2 EWSR1
5 li-fraumeni syndrome 32.2 TP53 MDM2 EGFR BCL2
6 liposarcoma 32.1 TP53 MDM2 EWSR1
7 muscle cancer 31.9 TP53 MDM2 FOXO1 EWSR1
8 leiomyosarcoma 31.6 VEGFA TP53 MDM2
9 retroperitoneal sarcoma 31.5 MDM2 EWSR1
10 embryonal sarcoma 31.3 TP53 MKI67 MDM2
11 dedifferentiated liposarcoma 31.3 TP53 MDM2 EWSR1
12 bone sarcoma 31.2 TP53 MDM2 EWSR1 CSF3
13 angiosarcoma 31.2 VEGFA TP53 MDM2
14 well-differentiated liposarcoma 31.1 TP53 MDM2 EWSR1
15 malignant peripheral nerve sheath tumor 31.0 TP53 MDM2 EGFR
16 embryonal rhabdomyosarcoma 31.0 TP53 MDM2 FOXO1 EWSR1
17 connective tissue benign neoplasm 30.9 TP53 MDM2 EWSR1
18 myxofibrosarcoma 30.9 TP53 MKI67 MDM2 EWSR1
19 gastrointestinal stromal tumor 30.9 VEGFA TP53 MKI67 EGFR ABCB1
20 rhabdomyosarcoma 30.8 VEGFA TP53 MDM2 FOXO1 EWSR1 EGFR
21 cellular myxoid liposarcoma 30.7 MDM2 EWSR1
22 sarcoma 30.7 VEGFA TP53 MDM2 FOXO1 EWSR1 ABCB1
23 osteogenic sarcoma 30.7 TP53 TNF MDM2 ABCB1
24 stomatitis 30.7 TNF IFNG CSF3
25 granulocytopenia 30.6 TNF CSF3
26 fasciitis 30.5 TP53 TNF IFNG
27 doxorubicin induced cardiomyopathy 30.4 EGFR CSF3
28 bone osteosarcoma 30.4 TP53 MDM2 EWSR1
29 skin melanoma 30.3 TP53 MKI67 MDM2
30 lymphangiosarcoma 30.2 VEGFA TNF
31 mucositis 30.2 VEGFA CSF3 ABCB1
32 ring chromosome 30.1 TP53 MDM2 EWSR1
33 cystitis 30.1 VEGFA TP53 TNF
34 neutropenia 30.1 TP53 TNF IFNG CSF3 ABCB1
35 toxic shock syndrome 30.1 TNF IFNG EGFR
36 b-cell lymphoma 30.0 TP53 MKI67 MDM2 BCL2
37 suppressor of tumorigenicity 3 30.0 TP53 BCL2
38 chordoma 29.9 VEGFA TP53 EGFR
39 female breast cancer 29.8 TP53 TNF EGFR
40 osteonecrosis 29.7 VEGFA TNF ABCB1
41 neurofibroma 29.7 VEGFA TP53 EGFR
42 appendicitis 29.7 TNF IFNG CSF3
43 acute graft versus host disease 29.6 TNF IFNG CSF3
44 osteomyelitis 29.6 TNF IFNG CSF3
45 gastric ulcer 29.6 VEGFA TP53 TNF
46 aspergillosis 29.6 TNF IFNG CSF3
47 inflammatory myofibroblastic tumor 29.6 TP53 MKI67 MDM2 EWSR1 BCL2
48 ewing sarcoma 29.6 VEGFA TP53 MDM2 FOXO1 EWSR1 EGFR
49 peritonitis 29.5 TNF IFNG CSF3
50 meningioma, familial 29.5 VEGFA TP53 MKI67 EGFR

Graphical network of the top 20 diseases related to Soft Tissue Sarcoma:



Diseases related to Soft Tissue Sarcoma

Symptoms & Phenotypes for Soft Tissue Sarcoma

MGI Mouse Phenotypes related to Soft Tissue Sarcoma:

45 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.3 ABCB1 BCL2 EGFR FOXO1 IFNG LATS1
2 hematopoietic system MP:0005397 10.29 ABCB1 BCL2 CSF3 EGFR FOXO1 IFNG
3 endocrine/exocrine gland MP:0005379 10.27 ABCB1 BCL2 EGFR FOXO1 IFNG LATS1
4 behavior/neurological MP:0005386 10.26 ABCB1 BCL2 FOXO1 IFNG LATS1 MDM2
5 growth/size/body region MP:0005378 10.26 ABCB1 BCL2 EGFR FOXO1 IFNG LATS1
6 immune system MP:0005387 10.26 ABCB1 BCL2 CSF3 EGFR FOXO1 IFNG
7 cellular MP:0005384 10.25 BCL2 EGFR FOXO1 IFNG LATS1 MDM2
8 digestive/alimentary MP:0005381 10.24 ABCB1 BCL2 EGFR FOXO1 IFNG MDM2
9 homeostasis/metabolism MP:0005376 10.24 ABCB1 BCL2 EGFR FOXO1 IFNG LATS1
10 integument MP:0010771 10.21 BCL2 CSF3 EGFR FOXO1 IFNG LATS1
11 craniofacial MP:0005382 10.19 BCL2 EGFR FOXO1 IFNG MDM2 TNF
12 embryo MP:0005380 10.18 BCL2 EGFR FOXO1 IFNG MDM2 TNF
13 mortality/aging MP:0010768 10.16 ABCB1 BCL2 EGFR FOXO1 IFNG LATS1
14 liver/biliary system MP:0005370 10.13 ABCB1 EGFR FOXO1 IFNG LATS1 MDM2
15 nervous system MP:0003631 10.07 ABCB1 BCL2 EGFR FOXO1 IFNG LATS1
16 neoplasm MP:0002006 10.06 BCL2 EGFR FOXO1 IFNG LATS1 MDM2
17 muscle MP:0005369 10.03 BCL2 EGFR FOXO1 IFNG MDM2 TNF
18 no phenotypic analysis MP:0003012 10.02 ABCB1 EGFR FOXO1 IFNG LATS1 MDM2
19 limbs/digits/tail MP:0005371 9.97 EGFR FOXO1 MDM2 TNF TP53 VEGFA
20 normal MP:0002873 9.86 EGFR FOXO1 IFNG LATS1 MDM2 MKI67
21 renal/urinary system MP:0005367 9.7 BCL2 CSF3 EGFR IFNG MDM2 TP53
22 reproductive system MP:0005389 9.65 ABCB1 BCL2 EGFR FOXO1 IFNG LATS1
23 skeleton MP:0005390 9.23 EGFR FOXO1 IFNG LATS1 MDM2 TNF

Drugs & Therapeutics for Soft Tissue Sarcoma

Drugs for Soft Tissue Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 595)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lopinavir Approved Phase 4 192725-17-0 92727
2
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
3
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
4
Aprepitant Approved, Investigational Phase 4 170729-80-3 6918365 151165
5
Tranexamic Acid Approved Phase 4 1197-18-8 5526
6
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
7
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
8
Dalteparin Approved Phase 4 9005-49-6
9
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
10
Enoxaparin Approved Phase 4 9005-49-6 772
11 Cytochrome P-450 CYP3A Inhibitors Phase 4
12 Hemostatics Phase 4
13 Antifibrinolytic Agents Phase 4
14 Coagulants Phase 4
15 Fibrinolytic Agents Phase 4
16 calcium heparin Phase 4
17 Anticoagulants Phase 4
18 Heparin, Low-Molecular-Weight Phase 4
19 Platelet Aggregation Inhibitors Phase 4
20 Antipyretics Phase 4
21
Morphine Approved, Investigational Phase 3 57-27-2 5288826
22
Meloxicam Approved, Vet_approved Phase 3 71125-38-7 54677470 5281106
23
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
24
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
25
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
26
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
27
Nicotine Approved Phase 3 54-11-5 942 89594
28
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
29
Abacavir Approved, Investigational Phase 2, Phase 3 136470-78-5 441300 65140
30
Sulfamethoxazole Approved Phase 3 723-46-6 5329
31
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
32
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
33
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
34
Varenicline Approved, Investigational Phase 3 249296-44-4 5310966
35
Olaparib Approved Phase 3 763113-22-0 23725625
36
Epirubicin Approved Phase 3 56420-45-2 41867
37
Ceritinib Approved Phase 3 1032900-25-6
38
Palbociclib Approved, Investigational Phase 3 571190-30-2 5005498 11431660 5330286
39
Denosumab Approved Phase 3 615258-40-7
40
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
41
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
42
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
43
Daunorubicin Approved Phase 3 20830-81-3 30323
44
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
45
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
46
Idarubicin Approved Phase 3 58957-92-9 42890
47
Bortezomib Approved, Investigational Phase 3 179324-69-7 387447 93860
48
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
49
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
50
Cetuximab Approved Phase 3 205923-56-4 56842117 2333

Interventional clinical trials:

(show top 50) (show all 1790)
# Name Status NCT ID Phase Drugs
1 EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Unknown status NCT00339118 Phase 4 doxorubicin, cytoxan
2 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
3 A Randomized Comparison of Protease Inhibitor-based Versus Non-nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy for Initial Treatment of Individuals With AIDS-related Kaposi's Sarcoma in Sub-Saharan Africa Completed NCT00444379 Phase 4 Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
4 A Prospective Randomized Trial Comparing the Response of HIV Kaposi's Sarcoma (KS) to HAART Versus the Combination of HAART and Chemotherapy (CXT) Completed NCT00380770 Phase 4 Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
5 Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma Recruiting NCT03514381 Phase 4 Patients starting a treatment with Doxorubicin and Ifosfamide
6 Prospective, Randomized Evaluation of Hyperbaric Oxygen Therapy on Wound Healing Following Management of Soft Tissue Sarcoma With Neo-Adjuvant Radiation and Surgical Resection Recruiting NCT03144206 Phase 4 Hyperbaric oxygen
7 Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule Recruiting NCT04223583 Phase 4 Anlotinib Hydrochloride
8 Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib — a Randomized, Controlled Trial Recruiting NCT03735758 Phase 4 pazopanib or guideline conform chemotherapy
9 Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma: a Single Arm Prospective Study Recruiting NCT04056962 Phase 4 Tacrolimus ointment
10 An Open Label, Multicenter, Non-Comparative, Phase IV Study of Panitumumab to Characterize Its Safety, Tolerability and Activity in Indian Subjects With Previously Treated Wild-Type RAS (KRAS and NRAS), Metastatic Colorectal Cancer Recruiting NCT02301962 Phase 4 Panitumumab
11 Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction: A Randomized Controlled Trial Recruiting NCT04347122 Phase 4 Tranexamic Acid (TXA)
12 Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma:A Prospective, Randomized Open Trial Recruiting NCT04077515 Phase 4 Sirolimus(0.8mg/m2);Sirolimus(0.7mg/m2)
13 Low Molecular Weight Heparin Versus Aspirin for Venous Thromboembolism Prophylaxis in Orthopaedic Oncology Enrolling by invitation NCT03244020 Phase 4 Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
14 Registry of Retroperitoneal, Abdominal, Pelvic and Truncal Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet® to Evaluate the Safety and Feasibility Over 5 Years Not yet recruiting NCT04033081 Phase 4
15 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Unknown status NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
16 A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Soft Tissue Sarcoma Unknown status NCT02449343 Phase 2, Phase 3 Anlotinib;Placebo
17 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
18 A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS) Unknown status NCT01344018 Phase 3
19 MULTICENTER RANDOMIZED, OPEN-LABEL PHASE II/III STUDY, TO COMPARE EFFICACY OF NBTXR3 IMPLANTED AS INTRATUMOR INJECTION AND ACTIVATED BY RADIOTHERAPY, VERSUS RADIOTHERAPY ALONE IN PATIENTS WITH LOCALLY ADVANCED SOFT TISSUE SARCOMA (EXTREMITY AND TRUNK WALL) Unknown status NCT02379845 Phase 2, Phase 3
20 Phase III Study of The Role of Barrier Resection in Local Control in Treatment of Extremity Soft Tissue Sarcomas Unknown status NCT02120768 Phase 3
21 A Protocol For Nonmetastatic Rhabdomyosarcoma [RMS-2005] Unknown status NCT00379457 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
22 Phase III Study About the Effects of the Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3 doxorubicin, ifosfamide, cisplatin
23 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Adriamycin, Bleomycin, and Vincristine (ABV) in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
24 EUROPEAN INTERGROUP COOPERATIVE EWING'S SARCOMA STUDY [EICESS 92] Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
25 Intensified Methotrexate, Vinblastine, Doxorubicin and Cisplatin +/-Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma in Patients Without Harvey Nor Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations. Phase II Study Unknown status NCT02818725 Phase 3 Chemotherapy;panitumumab
26 European Ewing Tumour Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99) Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
27 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
28 A Double-Blind Randomized Placebo Controlled Trial for Prevention of Tuberculosis-Immune Reconstitution Inflammatory Syndrome With Non-Steroid Anti-Inflammatory Drugs (NSAIDs) in HIV-Infected Adults Unknown status NCT02060006 Phase 3 Meloxicam 7.5mg daily for 8 weeks
29 Prospective and Randomized Study of Fixed Versus Flexible Prophylactic Administration of Granulocyte Colony-Stimulating Factor (G-CSF) in Children With Cancer Unknown status NCT01987596 Phase 3
30 Comparing the Effectiveness of Combined Hyperthermia and External Beam Radiation (EBRT) Versus EBRT Alone in Treating Patients With Painful Bone Metastases Unknown status NCT01842048 Phase 3
31 Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine and Irinotecan (VI) for Patients With Intermediate-Risk Rhabdomyosarcoma (RMS) Unknown status NCT00354835 Phase 3 Irinotecan Hydrochloride;Cyclophosphamide;Vincristine Sulfate
32 A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Completed NCT00753688 Phase 3 PAZOPANIB;Placebo
33 A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator's Choice in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy Completed NCT02049905 Phase 3 Aldoxorubicin;Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
34 Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX] Completed NCT00423618 Phase 3
35 Ph III Random Trial of 120-Min Infusion Gemcitabine v. 90-Min Infusion Gemcitabine + Docetaxel in Unresectable Soft Tissue Sarcoma: A Multi-Disciplinary Trial of the North Amer. Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00142571 Phase 3 Gemcitabine;Docetaxel
36 A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcomas (RPS) Completed NCT00091351 Phase 3
37 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
38 A Phase III Multicenter, International, Randomized, Double-blind, Placebo-controlled Study of Doxorubicin Plus Palifosfamide-tris vs. Doxorubicin Plus Placebo in Patients With Front-line Metastatic Soft Tissue Sarcoma. Completed NCT01168791 Phase 3 doxorubicin in combination with palifosfamide-tris;doxorubicin in combination with placebo
39 A Randomized Phase III Trial Comparing Trabectedin (Yondelis®) to the Best Supportive Care in Patients With Advanced Soft Tissue Sarcoma Completed NCT02672527 Phase 3 Trabectedin;Dexamethasone
40 Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
41 Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
42 A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination With Doxorubicin vs. Doxorubicin Alone in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma Completed NCT01440088 Phase 3 TH-302 in Combination with Doxorubicin;Doxorubicin
43 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
44 Randomized Phase III Trial of Two Investigational Schedules of Ifosfamide vs. Standard Dose Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
45 A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma Completed NCT00001300 Phase 3 doxorubicin;ifosfamide;mesna
46 A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma Completed NCT01327885 Phase 3 Eribulin mesylate 1.4 mg/m^2 intravenous;Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV
47 A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies. Completed NCT00699517 Phase 3 OMBRABULIN (AVE8062);Placebo
48 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
49 Actinomycin D and Vincristine With or Without Radiation Therapy, for Newly Diagnosed Patients With Low-Risk Rhabdomyosarcoma or Undifferentiated Sarcoma: IRS-V Protocol Completed NCT00002995 Phase 3 cyclophosphamide;vincristine sulfate
50 Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients With High-Risk Rhabdomyosarcoma Completed NCT00354744 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate

Search NIH Clinical Center for Soft Tissue Sarcoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ifosfamide
Mitoxantrone
Mitoxantrone Hydrochloride
Thiotepa

Genetic Tests for Soft Tissue Sarcoma

Genetic tests related to Soft Tissue Sarcoma:

# Genetic test Affiliating Genes
1 Soft Tissue Sarcoma 29

Anatomical Context for Soft Tissue Sarcoma

MalaCards organs/tissues related to Soft Tissue Sarcoma:

40
Bone, Lung, T Cells, Breast, Uterus, Brain, Skin

Publications for Soft Tissue Sarcoma

Articles related to Soft Tissue Sarcoma:

(show top 50) (show all 7818)
# Title Authors PMID Year
1
Surgical and oncological outcomes after hindquarter amputation for pelvic sarcoma. 61 42
32475235 2020
2
A nomogram to predict metastasis of soft tissue sarcoma of the extremities. 61 42
32481285 2020
3
The value of clinical parameters combined with magnetic resonance imaging (MRI) features for preoperatively distinguishing different subtypes of uterine sarcomas: An observational study (STROBE compliant). 42
32311989 2020
4
Extracellular vesicle cross-talk in the liposarcoma microenvironment. 61
32470489 2020
5
Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself. 61
32333216 2020
6
Case report of intra-articular synovial sarcoma in the hip joint. 61
32577142 2020
7
Pelvic Leiomyosarcoma With Splenic Metastasis and Response Assessment by 18F-FDG PET/CT. 61
32404703 2020
8
Cytotoxic drugs in combination with the CXCR4 antagonist AMD3100 as a potential treatment option for pediatric rhabdomyosarcoma. 61
32377699 2020
9
Quantitative magnetic resonance imaging (q-MRI) for the assessment of soft-tissue sarcoma treatment response: a narrative case review of technique development. 61
32163847 2020
10
18F-FDG PET/CT Imaging of Adrenal Liposarcoma. 61
32453082 2020
11
A rare case of primary dermal clear cell sarcoma with focal epidermotropism: An entity difficult to distinguish from melanoma. 61
32012324 2020
12
Soft tissue sarcoma in children, adolescents and young adults: Outcomes according to compliance with international initial care guidelines. 61
31839437 2020
13
Complement and coagulation cascades pathway correlates with chemosensitivity and overall survival in patients with soft tissue sarcoma. 61
32339514 2020
14
Incidence of and risk factors for late cholecystectomy in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. 61
32422507 2020
15
Six-Week Interval Between Preoperative Radiation and Surgery Is Associated With Fewer Major Wound Complications in Soft Tissue Sarcoma. 61
32217853 2020
16
Is it time for a change in the model of care for AYA patients with soft tissue sarcoma? How to improve outcomes for patients aged 15-25 using a mixed pediatric-adult cancer care model in expert sarcoma centers. 61
32362467 2020
17
Isolated limb perfusion is an effective treatment modality for locally advanced Kaposi sarcoma of the extremities. 61
32359920 2020
18
Patterns of Prior and Subsequent Neoplasms in Children and Adolescents With Soft Tissue Sarcomas. 61
32576783 2020
19
Cabozantinib as an emerging treatment for sarcoma. 61
32541320 2020
20
Immunotherapy in sarcoma: combinations or single agents? In whom? 61
32541322 2020
21
A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma. 61
32141887 2020
22
Alveolar soft part sarcoma: A distinct cytomorphology and characteristic TFE3 staining. 61
32315502 2020
23
Novel therapeutic options for alveolar soft part sarcoma: antiangiogenic therapy, immunotherapy and beyond. 61
32541316 2020
24
Limb preserving surgery for soft-tissue sarcoma in the hand: a retrospective study of 51 cases. 61
31973665 2020
25
Paratesticular rhabdomyosarcoma-Impact of locoregional approach on patient outcome: A report from the European paediatric Soft tissue sarcoma Study Group (EpSSG). 61
32573979 2020
26
Impact of Local Control and Surgical Lymph Node Evaluation in Localized Paratesticular Rhabdomyosarcoma: A Report from the Children's Oncology Group Soft Tissue Sarcoma Committee. 61
32525556 2020
27
BET inhibition therapy counteracts cancer cell survival, clonogenic potential and radioresistance mechanisms in rhabdomyosarcoma cells. 61
32200036 2020
28
Optical coherence tomography imaging of excised canine apocrine gland anal sac adenocarcinoma tumors. 61
32562302 2020
29
Skeletal muscle measurements predict surgical wound complications but not overall survival in patients with soft tissue sarcoma. 61
32533175 2020
30
Oncologic outcomes of pre- versus post-operative radiation in Resectable soft tissue sarcoma: a systematic review and meta-analysis. 61
32576267 2020
31
Primary anatomical site as a prognostic factor for pleomorphic liposarcoma. 61
32248301 2020
32
Psychological functioning, coping styles and their relationship to appraisal of physical limitations following invasive surgical procedures for soft-tissue sarcoma: A qualitative study. 61
32221986 2020
33
The prognostic role of the preoperative systemic immune-inflammation index and high-sensitivity modified Glasgow prognostic score in patients after radical operation for soft tissue sarcoma. 61
32576479 2020
34
Complete Response to Dual Immunotherapy in a Young Adult with Metastatic Alveolar Soft Part Sarcoma Enabled by a Drug Recovery Program in a Community Practice. 61
31855495 2020
35
Dermatofibrosarcoma protuberans in children and adolescents: The European Paediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005). 61
32558231 2020
36
Desmoid tumor mimics local recurrence of extremity sarcoma on MRI. 61
32212166 2020
37
Soft Tissue Tumors of the Extremity. 61
32402308 2020
38
Diagnostic concordance between ultrasound-guided core needle biopsy and surgical resection specimens for histological grading of extremity and trunk soft tissue sarcoma. 61
32514582 2020
39
The landscape of gene mutations and clinical significance of tumor mutation burden in patients with soft tissue sarcoma who underwent surgical resection and received conventional adjuvant therapy. 61
32520634 2020
40
Factors affecting postmusculoskeletal tumour surgery wound problem treatment with negative pressure wound therapy. 61
32065733 2020
41
Novel method for fast trabectedin quantification using hydrophilic interaction liquid chromatography and tandem mass spectrometry for human pharmacokinetic studies. 61
32229403 2020
42
Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas. 61
32493964 2020
43
Time lapse analysis of tumor response in patients with soft tissue sarcoma treated with trabectedin: A pooled analysis of two phase II clinical trials. 61
32220056 2020
44
Cerebral metastasis from osteosarcoma: "Bone" in the brain. 61
32322331 2020
45
Cabozantinib as an emerging treatment for sarcoma. 61
32453033 2020
46
Alveolar soft part sarcoma of the lateral rectus muscle: Suture technique to prevent postoperative strabismus. 61
32322745 2020
47
Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. 61
32524189 2020
48
Resection of pancreatic and splenic metastases from alveolar soft part sarcoma: a case report. 61
32556799 2020
49
A durable complete response to immunotherapy in a patient with metastatic alveolar soft part sarcoma. 61
32567515 2020
50
Primary alveolar soft part sarcoma of the rectum resected by endoscopic submucosal dissection: A case report. 61
32515162 2020

Variations for Soft Tissue Sarcoma

Expression for Soft Tissue Sarcoma

Search GEO for disease gene expression data for Soft Tissue Sarcoma.

Pathways for Soft Tissue Sarcoma

Pathways related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 VEGFA TP53 TNF MDM2 IFNG FOXO1
2
Show member pathways
13.75 VEGFA TP53 TNF MDM2 FOXO1 EGFR
3
Show member pathways
13.34 TP53 TNF MDM2 FOXO1 EGFR CSF3
4
Show member pathways
13.22 VEGFA TP53 TNF IFNG FOXO1 EGFR
5
Show member pathways
13.15 TP53 TNF IFNG FOXO1 EGFR BCL2
6
Show member pathways
13 TP53 TNF IFNG EGFR BCL2
7
Show member pathways
12.87 VEGFA TP53 TNF MDM2 EGFR BCL2
8
Show member pathways
12.78 TP53 TNF MDM2 IFNG BCL2
9
Show member pathways
12.77 VEGFA TP53 MDM2 FOXO1 EGFR BCL2
10 12.64 VEGFA TP53 MDM2 IFNG FOXO1 EGFR
11
Show member pathways
12.63 TP53 MDM2 FOXO1 EGFR BCL2
12
Show member pathways
12.62 TP53 TNF IFNG EGFR
13
Show member pathways
12.59 VEGFA TP53 TNF MDM2 FOXO1 EGFR
14
Show member pathways
12.51 VEGFA TP53 MDM2 FOXO1 EGFR BCL2
15 12.47 TP53 MKI67 MDM2 LATS1
16
Show member pathways
12.47 TP53 TNF IFNG FOXO1 EGFR BCL2
17
Show member pathways
12.46 VEGFA TP53 MDM2 EGFR
18
Show member pathways
12.41 IFNG EGFR CSF3 BCL2
19
Show member pathways
12.41 TP53 MDM2 EGFR BCL2
20 12.37 VEGFA TP53 MDM2 EGFR BCL2 ABCB1
21 12.24 TP53 MDM2 FOXO1 EWSR1
22 12.23 VEGFA TP53 TNF MDM2 EGFR
23
Show member pathways
12.22 TP53 TNF IFNG EGFR
24
Show member pathways
12.19 TP53 MDM2 FOXO1 EGFR BCL2
25 12.12 TP53 TNF MDM2 FOXO1 EGFR BCL2
26 12.11 VEGFA TP53 TNF IFNG EGFR
27
Show member pathways
12.04 MDM2 FOXO1 EGFR
28 12.04 TP53 MDM2 EGFR BCL2
29 11.99 TP53 MDM2 FOXO1
30 11.99 TP53 TNF IFNG EGFR
31 11.98 TP53 TNF BCL2
32 11.97 VEGFA TP53 TNF IFNG BCL2
33 11.96 TNF IFNG CSF3
34 11.96 TP53 MDM2 BCL2
35 11.94 TP53 MDM2 FOXO1 EGFR
36 11.92 VEGFA IFNG EGFR BCL2
37 11.9 TP53 MDM2 IFNG BCL2
38 11.86 TP53 TNF BCL2
39 11.86 VEGFA TNF FOXO1 BCL2
40 11.85 VEGFA TNF IFNG
41 11.84 MDM2 FOXO1 EGFR
42 11.78 TP53 MDM2 IFNG
43 11.78 VEGFA TP53 TNF FOXO1 BCL2
44 11.72 TP53 MDM2 BCL2
45 11.7 VEGFA TP53 MDM2 EGFR
46 11.67 VEGFA TP53 MDM2 BCL2
47
Show member pathways
11.65 VEGFA TNF IFNG
48 11.62 VEGFA TP53 MDM2 FOXO1 EGFR BCL2
49 11.58 VEGFA TP53 MDM2
50 11.57 TP53 MDM2 FOXO1

GO Terms for Soft Tissue Sarcoma

Biological processes related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.13 VEGFA TP53 TNF FOXO1 EGFR CSF3
2 negative regulation of transcription, DNA-templated GO:0045892 10.03 TP53 TNF MDM2 IFNG FOXO1
3 negative regulation of transcription by RNA polymerase II GO:0000122 10 VEGFA TP53 TNF MDM2 IFNG FOXO1
4 positive regulation of apoptotic process GO:0043065 9.98 TP53 TNF LATS1 FOXO1
5 response to drug GO:0042493 9.96 TP53 MDM2 BCL2 ABCB1
6 positive regulation of gene expression GO:0010628 9.96 VEGFA TP53 TNF MDM2 IFNG
7 regulation of cell proliferation GO:0042127 9.89 TP53 TNF FOXO1 EGFR
8 response to oxidative stress GO:0006979 9.86 TP53 EGFR BCL2
9 positive regulation of cell proliferation GO:0008284 9.85 VEGFA MDM2 IFNG EGFR CSF3 BCL2
10 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.84 VEGFA TP53 CSF3
11 positive regulation of protein phosphorylation GO:0001934 9.84 VEGFA TNF IFNG EGFR
12 positive regulation of inflammatory response GO:0050729 9.83 TNF IFNG EGFR
13 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.81 VEGFA TNF MDM2
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 VEGFA TNF IFNG
15 negative regulation of gene expression GO:0010629 9.8 VEGFA TP53 TNF MDM2 IFNG
16 negative regulation of apoptotic process GO:0043066 9.8 VEGFA TP53 MDM2 FOXO1 EGFR BCL2
17 positive regulation of MAP kinase activity GO:0043406 9.77 VEGFA TNF EGFR
18 humoral immune response GO:0006959 9.76 TNF IFNG BCL2
19 positive regulation of protein localization to plasma membrane GO:1903078 9.74 TNF IFNG EGFR
20 cellular response to hypoxia GO:0071456 9.73 VEGFA TP53 MDM2 BCL2
21 positive regulation of protein complex assembly GO:0031334 9.72 VEGFA TNF IFNG
22 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.68 TNF IFNG
23 digestive tract morphogenesis GO:0048546 9.68 EGFR BCL2
24 cardiac septum morphogenesis GO:0060411 9.68 TP53 MDM2
25 positive regulation of chemokine biosynthetic process GO:0045080 9.67 TNF IFNG
26 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.67 TP53 EGFR
27 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.65 TP53 TNF
28 negative regulation of amyloid-beta clearance GO:1900222 9.65 TNF IFNG
29 response to salt stress GO:0009651 9.64 TP53 TNF
30 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.64 TNF IFNG
31 cytokine-mediated signaling pathway GO:0019221 9.63 VEGFA TP53 TNF FOXO1 CSF3 BCL2
32 cellular response to UV-C GO:0071494 9.62 TP53 MDM2
33 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.61 VEGFA TP53
34 T cell lineage commitment GO:0002360 9.61 TP53 BCL2
35 B cell lineage commitment GO:0002326 9.58 TP53 BCL2
36 cellular response to actinomycin D GO:0072717 9.51 TP53 MDM2
37 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.49 TNF IFNG
38 positive regulation of vitamin D biosynthetic process GO:0060557 9.48 TNF IFNG
39 positive regulation of nitrogen compound metabolic process GO:0051173 9.46 TNF IFNG
40 astrocyte activation GO:0048143 9.43 TNF IFNG EGFR
41 negative regulation of mitotic cell cycle GO:0045930 9.26 TP53 TNF EGFR BCL2
42 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.1 VEGFA TNF LATS1 EGFR CSF3 BCL2

Molecular functions related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.71 TP53 MDM2 EGFR CSF3
2 identical protein binding GO:0042802 9.7 VEGFA TP53 TNF MDM2 EWSR1 EGFR
3 cytokine activity GO:0005125 9.56 VEGFA TNF IFNG CSF3
4 protease binding GO:0002020 9.54 TP53 TNF BCL2
5 protein phosphatase binding GO:0019903 9.5 TP53 EGFR BCL2
6 protein phosphatase 2A binding GO:0051721 9.13 TP53 FOXO1 BCL2
7 ubiquitin protein ligase binding GO:0031625 9.1 TP53 MDM2 FOXO1 EGFR BCL2 ABCB1

Sources for Soft Tissue Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....